News Wire
Study: Dupilumab Showed Positive Phase 3 Results in Adolescents with Inadequately Controlled Eczema
"[dupilumab] blocks the IL-4/IL-13 pathway, which is emerging as a central driver of Type 2 allergic inflammation."
Study: IgG Antibodies Activate Blood Platelets and Contribute to the Severity of Anaphylaxis
"This work demonstrates the potential of exploring therapeutic interventions that target platelets as means of limiting the severity of anaphylactic shock."
Bacteria Therapy for Eczema Shows Promise in NIH Study
"We aim to alter the skin microbiome in a way that will relieve symptoms and free people from the burden of constant treatment."
FARE Calls on FDA to Act Swiftly On Reported EpiPen Shortage
The American Society of Health-System Pharmacists determined there was a national shortage of epinephrine auto-injectors covering two of the three manufacturers.
Discovery Could Lead To Personalized Medical Therapies for Emerging New Food Allergy Disorder
"Our goal is to provide the type of deep disease understanding and therapeutic decision-making that is now becoming routine in the cancer field."
FARE’s Annual Awareness Campaign Encourages Shining a Light on Food Allergy, a Serious Public...
This May, FARE is "Shining a Light" on food allergies and anaphylaxis as part of its annual Food Allergy Awareness Week campaign.
Innovative Research Partnership Addresses Needs of College Bound Students with Food Allergy
Researchers identify needs and work alongside designers to develop a toolkit to support safe transition to college for students with food allergy.
kaléo Announces First and Only FDA-Approved Epinephrine Auto-Injector for Infants and Toddlers
AUVI-q (epinephrine injection, USP) 0.1 mg auto-injector is specifically designed for infants and toddlers weighing 16.5 to 33 pounds (7.5 to 15 kilograms)
FARE Launches Updated Training Course for K-12 Schools
Newly revised educational course now available for free for schools nationwide.
Alpha-Gal Found to be Both a Medication and Red Meat Allergy
The typical reaction to alpha-gal is a delayed anaphylaxis three to six hours after exposure.
